Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort

被引：8

作者：

Sanchez-Bayona, Rodrigo ^{[1
]}

de Sa, Alfonso Lopez ^{[2
]}

Gilarranz, Yolanda Jerez ^{[3
]}

de Torre, Ana Sanchez ^{[4
]}

Alva, Manuel ^{[1
]}

Echavarria, Isabel ^{[3
]}

Moreno, Fernando ^{[2
]}

Tolosa, Pablo ^{[1
]}

Lopez, Blanca Herrero ^{[3
]}

de Luna, Alicia ^{[2
]}

Lema, Laura ^{[1
]}

Casado, Salvador Gamez ^{[3
]}

Madariaga, Ainhoa ^{[1
]}

Lopez-Tarruella, Sara ^{[3
]}

Manso, Luis ^{[1
]}

Bueno-Muino, Coralia ^{[4
]}

Garcia-Saenz, Jose A. ^{[2
]}

Ciruelos, Eva ^{[1
]}

Martin, Miguel ^{[3
]}

机构：

[1] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain

[2] Hosp Clin San Carlos, Med Oncol, Madrid, Spain

[3] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, C-Dr Esquerdo,46, Madrid 28007, Spain

[4] Hosp Univ Infanta Cristina, Med Oncol, Parla, Spain

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2024年 / 206卷 / 03期

关键词：

Metastatic breast cancer; Endocrine treatment; Everolimus; Hormone receptor positive; TREATMENT DECISION-MAKING; QUALITY-OF-LIFE; CARE; ACTIVATION; PARTICIPATION; PREFERENCES; PERCEPTIONS; CONCORDANCE; ROLES;

D O I：

10.1007/s10549-024-07324-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Everolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(-) advanced breast cancer (aBC) patients (pts) progressing during or after a non-steroidal aromatase inhibitor (NSAI). Since this approval, the treatment landscape of aBC has changed dramatically, particularly with the arrival of CDK 4-6 inhibitors. Endocrine monotherapy after progression to CDK4/6 inhibitors has shown a limited progression-free survival (PFS), below 3 months. Evidence of the efficacy of everolimus plus ET after CDK4/6 inhibitors is scarce. Methods A retrospective observational study of patients with aBC treated with everolimus and ET beyond CDK4/6-i progression compiled from February 2015 to December 2022 in 4 Spanish hospitals was performed. Clinical and demographic data were collected from medical records. The main objective was to estimate the median progression-free survival (mPFS). Everolimus adverse events (AE) were registered. Quantitative variables were summarized with medians; qualitative variables with proportions and the Kaplan-Meier method were used for survival estimates. Results One hundred sixty-one patients received everolimus plus ET (exemestane: 96, fulvestrant: 54, tamoxifen: 10, unknown: 1) after progressing on a CDK4/6 inhibitor. The median follow-up time was 15 months (interquartile range: 1-56 months). The median age at diagnosis was 49 years (range: 35-90 years). The estimated mPFS was 6.0 months (95%CI 5.3-7.8 months). PFS was longer in patients with previous CDK4/6 inhibitor therapy lasting for > 18 months (8.7 months, 95%CI 6.6-11.3 months), in patients w/o visceral metastases (8.0 months, 95%CI 5.8-10.5 months), and chemotherapy-na & iuml;ve in the metastatic setting (7.2 months, 95%CI 5.9-8.4 months). Conclusion This retrospective analysis cohort of everolimus plus ET in mBC patients previously treated with a CDK4/6 inhibitor suggests a longer estimated mPFS when compared with the mPFS with ET monotherapy obtained from current randomized clinical data. Everolimus plus ET may be considered as a valid control arm in novel clinical trial designs.

引用

页码：551 / 559

页数：9